WALTHAM, Mass., Sept. 22 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the Sachs Biotech in Europe Investor Forum Wednesday, September 29, 2010 at the Radisson Blu hotel in Zurich, Switzerland.
Dr. Horobin will be a panelist on the Oncology Investment Panel at 12:00 pm CEST. Her presentation will be given at 5:00 p.m. CEST and will include an overview of upcoming milestones including the ongoing phase 2 clinical program for entinostat in breast, lung, colorectal cancer and hematologic malignancies.
The presentation will be available at Syndax's website, www.syndax.com.
About SyndaxSyndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.
Syndax holds rights to entinostat from Bayer Schering Pharma and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit www.syndax.com.Contact InformationJoanna Horobin, M.D.
Danielle Bertrand Syndax Pharmaceuticals, Inc.
WCG Tel: 781-419-1402
Tel: 415-946-1056 email@example.com